A fourth COVID-19 vaccine may enter the market.
AstraZeneka has reportedly tested a new vaccine on over 32,000 people in a trial period within the United States. With the help of the University of Oxford, the vaccine is 79% effective in preventing symptomatic illness and 100% effective against severe disease and hospitalization. If approved for emergency use by the FDA, the AstraZeneca-Oxford vaccine will be the fourth on the market created to help combat the COVID-19 pandemic.
Compared to AstraZeneca’s 79% effectiveness, Moderna’s has an effectiveness of 94% and Pfizer-BioTech’s effectiveness of 95%.
On Monday, Ruud Dobber, executive vice president of AstraZeneca’s biopharmaceutical business unit, told CNBC’s Squawk Box, “We are thrilled by the results we have disclosed this morning.” AstraZeneka-Oxford will submit to the FDA in April for emergency usage.